Scope and Claims Analysis of US Patent 10,420,743 (United States) for Topical Acne Treatment Combining Tretinoin and Benzoyl Peroxide

US Patent 10,420,743 claims a method-of-treatment for acne using a specific dual-active topical regimen: tretinoin (or a pharmaceutically acceptable salt) at ~0.1% by weight and benzoyl peroxide at ~3% by weight, applied once daily for up to 12 weeks. The claims also add multiple layers of narrower patentability hooks: (i) “synergy” framed through safety and tolerability scoring vs. each monotherapy arm, (ii) efficacy superiority using lesion-count and IGA metrics, and (iii) product-quality and delivery constraints (storage stability of all-trans 5,6-epoxy retinoic acid and tretinoin degradation limits; tretinoin release rate; encapsulation in a shell, including inorganic shell types).

What exactly do the claims of US 10,420,743 cover for acne?

Core claim scope (Claim 1): A method of treating acne by once-daily topical application for up to 12 weeks of a topical medicament containing:

Tretinoin (or pharmaceutically acceptable salt), ~0.1% w/w
Benzoyl peroxide, ~3% w/w

This is a combination-treatment claim with an embedded regimen definition and fixed strength ranges by “about” content terms.

How broad is “about 0.1%” and “about 3%” in claim scope?

The claims use “about,” which typically expands coverage beyond exact nominal values, but the boundaries are driven by the specification’s taught ranges and any prosecution history. On the face of the claims alone, scope is centered on ~0.1% tretinoin and ~3% benzoyl peroxide, not higher-strength variants such as 0.05%, 0.025%, 0.1% gel products with different benzoyl peroxide strengths, or newer 5% benzoyl peroxide combinations.

What does “up to 12 weeks” mean for infringement windows?

The method is limited by a duration ceiling: treatment is applied “once a day for a period of time of up to 12 weeks.” That covers regimens that stop at or before 12 weeks. A regimen lasting beyond 12 weeks can fall outside the literal duration framing, unless the claim is construed to cover part of a longer course.

What does “topical medicament” require technically?

Claim 1 requires a topical medicament containing both actives. It does not require a specific dosage form by name (gel, cream, lotion), but later dependent claims do require release-rate characteristics and encapsulation/shell structures.

What “synergistically lower” safety/tolerability claims add (and how they narrow scope)?

US 10,420,743 includes dependent claims that tie treatment outcomes to synergy quantified by clinical scoring frameworks.

Claim 2: Synergistically lower Investigator Cutaneous Safety Assessment

Claim 2 narrows Claim 1 by requiring that at least one Investigator Cutaneous Safety Assessment parameter is synergistically lower for the combination regimen vs each active applied separately.

This is important because it converts an otherwise straightforward combination-concentration method into a performance-defined combination method.

Claim 3: Safety parameter set

Claim 3 further narrows the safety “synergy” parameter to:

erythema, scaling, pigmentation, or combinations.

Practical implication: A developer attempting to design around by changing vehicle, concentration, or delivery to maintain safety but not meet these specific scored parameters must address both the metric direction and the “synergy” framing.

Claim 4–5: Synergistically lower Local Tolerability Score

Claim 4 requires synergy lower in Local Tolerability Score vs monotherapy arms. Claim 5 defines tolerability parameters as:

itching, burning, stinging, or combinations.

Practical implication: The claims are not just “better than monotherapy,” but “synergistically lower” with respect to monotherapy comparators, which can create infringement or validity focus around trial design and statistical definitions.

What “synergistically higher” efficacy claims cover?

The patent also includes dependent claims that define synergy in efficacy endpoints.

Claim 21: Synergistically higher efficacy parameter

Claim 21 requires at least one efficacy parameter to be synergistically higher than with each active separately.

Claim 22: Defined efficacy endpoints

Claim 22 lists efficacy parameters:

IGA success rate
mean reduction in inflammatory lesions count
mean reduction in non-inflammatory lesion count
mean reduction in acne symptom domain
mean reduction in acne impact domain
mean reduction in verbal rating scale

Practical implication: The claim set covers multiple trial endpoint categories, reducing the risk that a challenger can avoid infringement by targeting a different efficacy metric, so long as the trial record supports at least one listed efficacy parameter.

What are the lesion-count and IGA improvement thresholds (Claims 7–12, 11)?

Lesion-count reductions

Claims 7–10 specify minimum reduction thresholds:

Claim 7: At least one of:
- inflammatory lesions reduced by ≥50%, or
- non-inflammatory lesions reduced by ≥40%
Claim 8: Non-inflammatory lesions reduced by ≥40%
Claim 9: Inflammatory lesions reduced by ≥50%
Claim 10: Both:
- inflammatory ≥50%
- non-inflammatory ≥40%

Claim 11: IGA success rate

Claim 11 requires:

IGA success rate improved by at least 20% compared to baseline score.

Practical implication: These threshold-dependent claims raise the evidentiary and design-around bar because efficacy outcomes are tied to measurable trial results. If an ANDA or alternative formulation cannot reproduce those outcomes under the claimed regimen, the literal claim may be harder to establish.

What product-quality and stability limitations are claimed?

Claims 12–13 introduce storage degradation constraints that function like formulation guardrails.

Claim 12: Degradation marker constraint after storage

After two weeks storage at 40°C, the concentration of:

all-trans 5,6-epoxy retinoic acid is lower than 1%.

Claim 13: Tretinoin degradation constraint after storage

After two weeks storage at 40°C:

degradation of tretinoin is less than 2.5%.

Scope effect: These dependent claims narrow coverage toward formulations that preserve tretinoin integrity and control epoxy retinoic acid formation under accelerated storage.

Design-around pressure point: Formulators changing the vehicle system, oxidation control approach, packaging, or encapsulation architecture may fail these specific post-storage chemical thresholds if not engineered to meet them.

What delivery/release requirements are claimed for tretinoin?

Claims 15–16 restrict tretinoin release kinetics.

Claim 15: Release rate limit

tretinoin release rate is <60% per hour.

Claim 16: Release rate limit in specific test medium

tretinoin release rate is <60% per hour in:
- 70% IPA (isopropyl alcohol) / 30% water at room temperature.

Scope effect: These dependent claims can be directly relevant to product characterization and to infringement analysis where release profiles are measured with matching test conditions.

Design-around pressure point: Alternative carriers, polymers, or microstructure approaches that alter diffusion can push release above the defined cap, potentially reducing risk against these dependent claims.

How far do the encapsulation/shell claims go (Claims 17–20)?

Encapsulation and shell structure claims are among the most technically specific elements of the patent and can be meaningful in formulation competition.

Claim 17: Encapsulation of at least one active in a shell

At least one active agent is:

encapsulated in a shell.

Claim 18: Both benzoyl peroxide and tretinoin encapsulated

Both actives are encapsulated in a shell.

Claim 19: Shell is inorganic

Shell is an inorganic shell.

Claim 20: Shell is metal oxide or semi-metal oxide inorganic shell

Shell is:

a metal oxide or semi-metal oxide shell.

Scope effect: These dependent claims can exclude a large subset of topical acne products that rely on non-inorganic microencapsulation, direct co-formulation without encapsulation, or organic polymer microcapsules.

Business relevance: In licensing or invalidity positioning, the encapsulation requirements create a potential divide:

if a competitor uses inorganic shell encapsulation with those actives, these dependent claims become directly relevant;
if not, the competitor can potentially avoid literal coverage of the encapsulation-specific dependents while still operating on Claim 1.

Single dose medicament requirement (Claim 6): does it matter?

Claim 6: Single dose medicament comprising both agents

Claim 6 narrows Claim 1 to a “single dose medicament” containing both actives.

Scope effect: This targets products where tretinoin and benzoyl peroxide are formulated together as one product, not administered as two separate topical compositions.

Design-around pressure point: If a competitor sells two separate products for combination use in parallel, that can raise arguments about whether the method uses a “single dose medicament” as required by dependent Claim 6 (though method claims can still be asserted under broader independent coverage depending on claim construction and asserted claim set).

How would claim architecture map to infringement theories?

Below is a claim-by-claim “infringement hook” map, based on the text provided.

Claim	What must be true to infringe (high level)	Primary infringement hook
1	Once-daily topical acne treatment up to 12 weeks using medicament with tretinoin ~0.1% + benzoyl peroxide ~3%	Actives + concentrations + regimen duration/frequency
2	Safety parameter shows “synergistically lower” vs each monotherapy	Clinical trial comparison framing
3	Safety parameter is erythema/scaling/pigmentation	Specific safety endpoints
4	Tolerability parameter shows “synergistically lower” vs each monotherapy	Clinical trial comparison framing
5	Local tolerability parameter is itching/burning/stinging	Specific tolerability endpoints
6	Same medicament contains both actives as one single dose	Formulation together vs separate products
7	≥50% inflammatory lesions reduction OR ≥40% non-inflammatory lesions reduction	Threshold efficacy outcomes
8	Non-inflammatory lesions ≥40% reduction	Threshold efficacy outcomes
9	Inflammatory lesions ≥50% reduction	Threshold efficacy outcomes
10	Both inflammatory and non-inflammatory thresholds met	Threshold efficacy outcomes
11	IGA success rate improves ≥20% vs baseline	IGA endpoint threshold
12	After 2 weeks at 40°C, all-trans 5,6-epoxy retinoic acid <1%	Chemical stability constraint
13	After 2 weeks at 40°C, tretinoin degradation <2.5%	Chemical stability constraint
14	Potentiates tretinoin action	Potentiation concept (trial support likely needed)
15	Release rate of tretinoin <60% per hour	Release kinetics constraint
16	Release rate <60% per hour in 70% IPA/30% water	Release kinetics with defined test medium
17	At least one active encapsulated in shell	Encapsulation requirement
18	Both actives encapsulated in shell	Encapsulation requirement
19	Shell is inorganic	Encapsulation requirement
20	Shell is metal oxide or semi-metal oxide	Specific inorganic shell chemistry
21	Efficacy parameter shows “synergistically higher” vs monotherapy	Clinical trial comparison framing
22	Synergistically higher parameter is one of listed efficacy domains	Endpoint list

What is the actionable “patent landscape” implication for competitors?

Even without file-history details, the claim text indicates the patent landscape is likely to be partitioned into three competitive design zones:

Zone A: Straight combination products at ~0.1% tretinoin + ~3% BPO

Products that match Claim 1 concentrations and regimen would still need to address whether dependents (synergy metrics, lesion thresholds, stability, release, encapsulation) are asserted.

Zone B: Same actives but altered vehicle delivery to move outside release and stability constraints

Competitors can potentially aim to:

increase tretinoin release rate above <60%/h (as measured in the specified medium) and/or
drive degradation markers above the stated thresholds after 40°C storage. These would not necessarily avoid Claim 1, but they can reduce exposure to dependents.

Zone C: Different microstructure (no inorganic shell encapsulation)

Competitors avoiding inorganic shell encapsulation can potentially defeat dependents 17–20. Claim 1 can still be asserted if the actives and regimen match.

When does US 10,420,743 expire, and how does exclusivity typically work?

No expiration, priority dates, patent term adjustment, or maintenance status are provided in the prompt. The provided input is insufficient to compute a concrete expiration date and exclusivity timeline.

Key Takeaways

US 10,420,743 is centered on a once-daily topical acne method for up to 12 weeks using a single medicament containing tretinoin ~0.1% w/w plus benzoyl peroxide ~3% w/w.
The claim set is not only concentration-driven. It layers trial-defined “synergy” outcomes for safety/tolerability and efficacy versus monotherapy comparators.
Multiple dependents are evidence-heavy (lesion-count thresholds, IGA success improvement, synergy framed across specific clinical score categories).
Multiple dependents are product-characterization-heavy (post-40°C storage chemical stability limits and tretinoin release-rate caps in a defined solvent system).
The encapsulation dependents constrain microstructure to inorganic shell encapsulation, up to metal oxide / semi-metal oxide shells for both actives.

FAQs

Does US 10,420,743 cover using tretinoin and benzoyl peroxide as two separate topical products?
Claim 6 requires a “single dose medicament” containing both actives, but Claim 1 itself requires the method uses a topical medicament consisting of both actives. Literal scope depends on which claims are asserted.
What clinical endpoints are explicitly tied to “synergy” in US 10,420,743?
Safety/tolerability: erythema, scaling, pigmentation; itching, burning, stinging. Efficacy: IGA success rate, inflammatory and non-inflammatory lesion count reductions, acne symptom domain, acne impact domain, and verbal rating scale.
Are chemical stability limits part of the method-of-treatment claims or a separate product limitation?
They appear as dependent method features tied to the topical medicament’s post-storage chemical profiles (all-trans 5,6-epoxy retinoic acid and tretinoin degradation after 40°C storage).
How do the release-rate claims affect formulation design around US 10,420,743?
They impose a <60% per hour release-rate cap in a specific test medium (70% IPA/30% water), which can be addressed by changing the formulation’s diffusion and release mechanism.
Which dependent claims require encapsulation, and how specific are they?
Claims 17–20 require encapsulation in a shell, then restrict the shell to inorganic forms, and further to metal oxide or semi-metal oxide shells, with Claim 18 requiring both benzoyl peroxide and tretinoin encapsulated.

References

No sources are provided in the prompt for US Patent 10,420,743 (e.g., USPTO bibliographic record, specification text, prosecution history, maintenance status, or Orange Book listings). Therefore, no citable references can be listed.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	10,420,743	⤷ Start Trial				TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3069287	⤷ Start Trial
China	110891561	⤷ Start Trial
European Patent Office	3651755	⤷ Start Trial
Japan	2020527143	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2019012536	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 10,420,743